Oppenheimer Asset Management Inc. raised its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 2.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 235,782 shares of the biopharmaceutical company’s stock after purchasing an additional 5,177 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Bristol-Myers Squibb were worth $14,912,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in BMY. Bellevue Group AG purchased a new stake in shares of Bristol-Myers Squibb in the first quarter worth about $2,530,000. Canandaigua National Bank & Trust Co. lifted its holdings in shares of Bristol-Myers Squibb by 1.8% in the first quarter. Canandaigua National Bank & Trust Co. now owns 56,569 shares of the biopharmaceutical company’s stock worth $3,578,000 after buying an additional 995 shares in the last quarter. Glen Harbor Capital Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 19.2% in the first quarter. Glen Harbor Capital Management LLC now owns 21,152 shares of the biopharmaceutical company’s stock worth $1,338,000 after buying an additional 3,408 shares in the last quarter. Centerpoint Advisors LLC lifted its holdings in shares of Bristol-Myers Squibb by 373.1% in the first quarter. Centerpoint Advisors LLC now owns 1,774 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 1,399 shares in the last quarter. Finally, KBC Group NV lifted its holdings in shares of Bristol-Myers Squibb by 16.2% in the first quarter. KBC Group NV now owns 371,225 shares of the biopharmaceutical company’s stock worth $23,480,000 after buying an additional 51,770 shares in the last quarter. 71.29% of the stock is currently owned by institutional investors and hedge funds.
In other Bristol-Myers Squibb news, Director Dinesh C. Paliwal purchased 4,770 shares of Bristol-Myers Squibb stock in a transaction on Monday, April 30th. The shares were acquired at an average cost of $52.40 per share, for a total transaction of $249,948.00. Following the completion of the transaction, the director now directly owns 8,027 shares of the company’s stock, valued at $420,614.80. The purchase was disclosed in a filing with the SEC, which is available at this link. 0.12% of the stock is owned by company insiders.
Shares of BMY opened at $52.34 on Wednesday. The company has a market capitalization of $85.39 billion, a P/E ratio of 17.39, a P/E/G ratio of 1.31 and a beta of 0.99. The company has a current ratio of 1.52, a quick ratio of 1.39 and a debt-to-equity ratio of 0.45. Bristol-Myers Squibb Co has a 1-year low of $49.96 and a 1-year high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 26th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.09. The business had revenue of $5.19 billion for the quarter, compared to the consensus estimate of $5.25 billion. Bristol-Myers Squibb had a net margin of 4.37% and a return on equity of 37.56%. Bristol-Myers Squibb’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period last year, the firm posted $0.84 earnings per share. analysts anticipate that Bristol-Myers Squibb Co will post 3.41 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th were given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 3.06%. The ex-dividend date of this dividend was Thursday, April 5th. Bristol-Myers Squibb’s payout ratio is currently 53.16%.
A number of brokerages have recently issued reports on BMY. BMO Capital Markets lowered their price target on shares of Bristol-Myers Squibb from $51.00 to $47.00 and set an “underperform” rating on the stock in a report on Wednesday, April 18th. Credit Suisse Group set a $58.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Thursday, April 26th. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Monday, January 29th. TheStreet downgraded shares of Bristol-Myers Squibb from a “b” rating to a “c+” rating in a report on Thursday, March 8th. Finally, Morgan Stanley downgraded shares of Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $54.08 to $58.00 in a report on Tuesday, April 17th. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $62.84.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.